Search

Your search keyword '"Vencovský, Jiří"' showing total 480 results
Start Over Author "Vencovský, Jiří"
480 results on '"Vencovský, Jiří"'

1. Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years.

Author

Choy, Ernest, Furst, Daniel, Vencovský, Jiří, Wilson, Anthony, Burmester, Gerd, Coombs, Derek, Penn, Sara, Khan, Nasser, Yee, Jillian, Rahawi, Kassim, McInnes, Iain, Giles, Jon, Lane, Nancy, and Charles-Schoeman, Christina

Subjects
JAK inhibitor, Laboratory parameters, Rheumatoid arthritis, Upadacitinib
Abstract

INTRODUCTION: Upadacitinib (UPA) is a Janus kinase inhibitor that has demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA) with an acceptable safety profile. We investigated laboratory parameter changes in UPA RA clinical trials. METHODS: Pooled data from six randomized trials in the SELECT phase 3 program were included. Key laboratory parameters and safety data were measured for UPA 15 and 30 mg once daily (QD), adalimumab (ADA) 40 mg every other week + methotrexate (MTX), and MTX monotherapy. Exposure-adjusted event rates (EAERs) of adverse events were calculated. RESULTS: A total of 3209 patients receiving UPA 15 mg QD (10 782.7 patient-years [PY]), 1204 patients receiving UPA 30 mg QD (3162.5 PY), 579 patients receiving ADA + MTX (1573.2 PY), and 314 patients receiving MTX monotherapy (865.1 PY) were included, representing up to 6.5 years of total exposure. Decreases in mean levels of hemoglobin, neutrophils, and lymphocytes, and increases in mean levels of liver enzymes and creatinine phosphokinase were observed with UPA, with grade 3 or 4 changes observed in some patients. Mean low- and high-density lipoprotein cholesterol ratios remained stable for patients receiving UPA 15 mg QD. EAERs of anemia and neutropenia occurred at generally consistent rates between UPA and active comparators (3.1-4.3 and 1.7-5.0 events [E]/100 PY across treatment groups, respectively). Rates of hepatic disorder were higher with MTX monotherapy, UPA 15 mg and UPA 30 mg (10.8, 9.7, and 11.0 E/100 PY, respectively) versus ADA + MTX (6.4 E/100 PY). Rates of lymphopenia were highest with MTX monotherapy (3.2 E/100 PY). Treatment discontinuations due to laboratory-related events were rare, occurring in 1.1% and 2.2% of patients treated with UPA 15 and 30 mg QD, respectively. CONCLUSIONS: The results of this integrated long-term analysis of laboratory parameters continue to support an acceptable safety profile of UPA 15 mg QD for moderate-to-severe RA.

Published
2024

4. Discovery of new myositis genetic associations through leveraging other immune-mediated diseases

Author

Reales, Guillermo, Amos, Christopher I., Benveniste, Olivier, Chinoy, Hector, De Bleecker, Jan, De Paepe, Boel, Doria, Andrea, Gregersen, Peter K., Lamb, Janine A., Limaye, Vidya, Lundberg, Ingrid E., Machado, Pedro M., Maurer, Britta, Miller, Frederick W., Molberg, Øyvind, Pachman, Lauren M., Padyukov, Leonid, Radstake, Timothy R., Reed, Ann M., Rider, Lisa G., Rothwell, Simon, Selva-O'Callaghan, Albert, Vencovský, Jiri, Wedderburn, Lucy R., and Wallace, Chris

Published
2024
Full Text
View/download PDF

5. Autoantibodies and damage in patients with idiopathic inflammatory myopathies: A longitudinal multicenter study from the MYONET international network

Author

Espinosa-Ortega, Fabricio, Lodin, Karin, Dastmalchi, Maryam, Vencovsky, Jiri, Diederichsen, Louise P, Shinjo, Samuel Katsuyuki, Danieli, Maria Giovanna, Selva-O'Callaghan, Albert, de Visser, Marianne, Griger, Zoltan, Ceribelli, Angela, Gómez-Martin, Diana, Andersson, Helena, Vázquez-Del Mercado, Mónica, Chinoy, Hector, Lilleker, James B, New, Paul, Krogh, Niels S, Lundberg, Ingrid E, and Alexanderson, Helene

Published
2024
Full Text
View/download PDF

6. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

Author

Linde, Louise, Ørnbjerg, Lykke M., Rasmussen, Simon H., Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K., Kvien, Tore K., Rodrigues, Ana M., Santos, Maria J., Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J., Ciurea, Adrian, Macfarlane, Gary J., Heddle, Maureen, Glintborg, Bente, Østergaard, Mikkel, and Hetland, Merete L.

Published
2023
Full Text
View/download PDF

9. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

Author

Christiansen, Sara Nysom, Horskjær Rasmussen, Simon, Pons, Marion, Michelsen, Brigitte, Glintborg, Bente, Gudbjornsson, Bjorn, Grondal, Gerdur, Vencovsky, Jiri, Loft, Anne Gitte, Rotar, Ziga, Pirkmajer, Katja Perdan, Nissen, Michael J., Baranová, Jana, Macfarlane, Gary J., Jones, Gareth T., Iannone, Florenzo, Caporali, Roberto, Laas, Karin, Vorobjov, Sigrid, Giuseppe, Daniela Di, Olofsson, Tor, Provan, Sella Aarrestad, Fagerli, Karen Minde, Castrejon, Isabel, Otero-Varela, Lucia, van de Sande, Marleen, van der Horst-Bruinsma, Irene, Nordström, Dan, Kuusalo, Laura, Bernardes, Miguel, Hetland, Merete Lund, Østergaard, Mikkel, and Midtbøll Ørnbjerg, Lykke

Published
2024
Full Text
View/download PDF

11. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Author

Michelsen, Brigitte, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian, Möller, Burkhard, Ørnbjerg, Lykke Midtbøll, Zavada, Jakub, Glintborg, Bente, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Ziga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovsky, Jiri, Loft, Anne Gitte, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José, Mogosan, Corina, Tomsic, Matija, Díaz-González, Federico, Di Giuseppe, Daniela, and Hetland, Merete Lund

Published
2023
Full Text
View/download PDF

12. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies

Author

Bianchi, Matteo, Kozyrev, Sergey V., Sandling, Johanna K., Rönnblom, Lars, Eloranta, Maija-Leena, Syvänen, Ann-Christine, Leonard, Dag, Dahlqvist, Johanna, Lidén, Maria, Mathioudaki, Argyri, Meadows, Jennifer RS., Nordin, Jessika, Nordmark, Gunnel, Lundberg, Ingrid E., Notarnicola, Antonella, Padyukov, Leonid, Tjärnlund, Anna, Dastmalchi, Maryam, Eriksson, Daniel, Molberg, Øyvind, Andersson, Helena, Lindblad-Toh, Kerstin, Farias, Fabiana H.G., Wahren-Herlenius, Marie, Jalal, Awat, Hanna, Balsam, Hellström, Helena, Husmark, Tomas, Häggström, Åsa, Svärd, Anna, Skogh, Thomas, Diederichsen, Louise Pyndt, Lamb, Janine A., Rothwell, Simon, Chinoy, Hector, Cooper, Robert G., Pielberg, Gerli Rosengren, Lobell, Anna, Karlsson, Åsa, Murén, Eva, Ahlgren, Kerstin M., Andersson, Göran, Landegren, Nils, Kämpe, Olle, Söderkvis, Peter, Leclair, Valérie, Galindo-Feria, Angeles S., Kryštůfková, Olga, Zargar, Sepehr Sarrafzadeh, Mann, Herman, Klein, Martin, Tansley, Sarah, McHugh, Neil, Vencovský, Jiri, Holmqvist, Marie, and Diaz-Gallo, Lina-Marcela

Published
2023
Full Text
View/download PDF

13. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

Author

Dahou, Brahim, Gómez, Gimena, Roberts, Karen, Baez, Roberto M, Castro Coello, Vanessa V, Haye Salinas, María J, Maldonado, Federico N, Reyes, Alvaro A, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan A, Schmid, Maria M, Cosatti, Micaela, Gamba, Maria J, Leandro, Carlevaris, Cusa, María A, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria S, Medina, María A, Savio, Veronica, Rojas Tessel, Romina, Alamino, Rodolfo P, Werner, Marina L, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Maria A, Rodriguez Gil, Gustavo F, Risueño, Fabian, Quaglia, Maria I, Scafati, Julia, Cuchiaro, Natalia L, Rebak, Jonathan E, Pineda, Susana I, Calvo, María E, Picco, Eugenia, Yanzi, Josefina G, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta S, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José L, Kisluk, Boris, Castaños Menescardi, Maria S, Gallo, Rosana, Martire, María V, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina S, Aeschlimann, Carolina, Subils, Gisela, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra L, Pinheiro, Marcelo, Ibáñez, Sebastián, Chassin Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešić, Marko, Anić, Branimir, Ćulo, Melanie-Ivana, Pavelić, Tea A, Stranski, Kristina K, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela M, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zazueta Montiel, Beatriz E, Castillo Ortiz, Angel A, Zamora Tehozol, Erick, Vega Morales, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez Reyna, Tatiana S, Rull Gabayet, Marina, Alpízar Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte Gil, Manuel, Nowakowski, Jarosław, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria M, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Mičeková, Dagmar, Capova, Lubica, Macejova, Zelmira, Šteňová, Emőke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Senčarová, Marieta, Žlnayová, Soňa, Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre Rubio, Natalia, Alegre Sancho, Juan J, Corteguera Coro, Montserrat, Cobeta Garcia, Juan C, Torres Martin, Maria C, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd K, Akar, Servet, Icacan, Ozan C, ÇELİK, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline M, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, Todd, Derrick, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio, Karen, Webb Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Ezzati, Fatemeh, Parks, Deborah, Karp, David, Quiceno, Guillermo, Izadi, Zara, Gianfrancesco, Milena A, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Ja, Clairissa, Taylor, Tiffany, Shidara, Kie, Danila, Maria I, Wysham, Katherine D, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte-García, Alí, Valenzuela-Almada, Maria O, Ugarte-Gil, Manuel F, Ljung, Lotta, Scirè, Carlo A, Carrara, Greta, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Thomas, Thierry, Santos, Maria J, Bernardes, Miguel, Hasseli, Rebecca, Regierer, Anne, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Pons-Estel, Guillermo, Nieto, Romina E, Pisoni, Cecilia N, Tissera, Yohana S, Xavier, Ricardo, Lopes Marques, Claudia D, Pileggi, Gecilmara C S, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Gore-Massy, Monique, Wallace, Zachary S, and Yazdany, Jinoos

Published
2022
Full Text
View/download PDF

15. A predictive model for progression to clinical arthritis in at-risk individuals with arthralgia based on lymphocyte subsets and ACPA.

Author

Prajzlerová, Klára, Kryštůfková, Olga, Kaspříková, Nikola, Růžičková, Nora, Hulejová, Hana, Hánová, Petra, Vencovský, Jiří, Šenolt, Ladislav, and Filková, Mária

Subjects
RHEUMATOID arthritis risk factors, RISK assessment, FLOW cytometry, PREDICTION models, T cells, KILLER cells, RESEARCH funding, AUTOANTIBODIES, ENZYME-linked immunosorbent assay, LOGISTIC regression analysis, IMMUNOGLOBULINS, LYMPHOCYTE subsets, JOINT pain, DISEASE progression, DISEASE complications
Abstract

Background The presence of ACPA significantly increases the risk of developing RA. Dysregulation of lymphocyte subpopulations was previously described in RA. Our objective was to propose the predictive model for progression to clinical arthritis based on peripheral lymphocyte subsets and ACPA in individuals who are at risk of RA. Methods Our study included 207 at-risk individuals defined by the presence of arthralgias and either additional ACPA positivity or meeting the EULAR definition for clinically suspect arthralgia. For the construction of predictive models, 153 individuals with symptom duration ≥12 months who have not yet progressed to arthritis were included. The lymphocyte subsets were evaluated using flow cytometry and anti-CCP using ELISA. Results Out of all individuals with arthralgia, 41 progressed to arthritis. A logistic regression model with baseline peripheral blood lymphocyte subpopulations and ACPA as predictors was constructed. The resulting predictive model showed that high anti-CCP IgG, higher percentage of CD4+ T cells, and lower percentage of T and NK cells increased the probability of arthritis development. Moreover, the proposed classification decision tree showed that individuals having both high anti-CCP IgG and low NK cells have the highest risk of developing arthritis. Conclusions We propose a predictive model based on baseline levels of lymphocyte subpopulations and ACPA to identify individuals with arthralgia with the highest risk of progression to clinical arthritis. The final model includes T cells and NK cells, which are involved in the pathogenesis of RA. This preliminary model requires further validation in larger at-risk cohorts. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

Author

Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra Lucia, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Castro Coello, Vanessa, Haye Salinas, María J., Maldonado, Federico Nicolas, Reyes Torres, Alvaro Andres, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria Soledad, Medina, María Alejandra, Savio, Veronica, Rojas Tessel, Ivana Romina, Perez Alamino, Rodolfo, Werner, Marina Laura, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Ma. Alicia, Rodriguez Gil, Gustavo Fabián, Risueño, Fabian, Quaglia, Maria Isabel, Scafati, Julia, Cuchiaro, Natalia Lili, Rebak, Jonathan Eliseo, Pineda, Susana Isabel, Calvo, María Elena, Picco, Eugenia, Gallino Yanzi, Josefina, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta Silvana, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José Luis, Kisluk, Boris, Castaños Menescardi, Maria Sol, Gallo, Rosana, Martire, María Victoria, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina Solange, Aeschlimann, Carolina, Subils, Gisela, Ibáñez, Sebastián, Chassin-Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešic, Marko, Anic, Branimir, Culo, Melanie-Ivana, Pavelic, Tea Ahel, Kovacevic Stranski, Kristina, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela Maria, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir-Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zaueta, Beatriz, Castillo Ortiz, Angel Alejandro, Zamora Tehozol, Erick, Vega, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez-Reyna, Tatiana Sofia, Rull Gabayet, Marina, Alpízar-Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts-van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al-Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte-Gil, Manuel, Nowakowski, Jaroslaw, Al-Emadi, Samar, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria Magdelena, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Miceková, Dagmar, Capova, Lubica, Macejova, Zelmira, Štenová, Emoke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Sencarová, Marieta, Žlnayová, Sona, Anna Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre-Rubio, Natalia, Alegre Sancho, Juan José, Corteguera Coro, Montserrat, Cobeta Garcia, Juan Carlos, Torres Martin, Maria Carmen, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd Kubra, Akar, Servet, Icacan, Ozan Cemal, Çelik, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline Mulvaney, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, D'Silva, Kristin, Hsu, Tiffany, Patel, Naomi, Sparks, Jeffrey, Todd, Derrick, Wallace, Zachary, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Wise, Leanna, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio Toribio, Karen, Webb-Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Fatemeh, Ezzati, Parks, Deborah, Karp, David, Quiceno, Guillermo, Sattui, Sebastian E, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, and Robinson, Philip C

Published
2021
Full Text
View/download PDF

17. Correspondence on ‘Current myositis clinical trials and tribulations’ by Sayginet al

Author

Azevedo, Sofia Ferreira, primary, Valenzuela, Antonia, additional, Benitez, Cristian Alejandro, additional, Isenberg, David A, additional, Naddaf, Elie, additional, Chinoy, Hector, additional, Vencovský, Jiří, additional, Gupta, Latika, additional, McCann, Liza, additional, Kuwana, Masataka, additional, Dimachkie, Mazen M, additional, Shenoi, Susan, additional, Saketkoo, Lesley Ann, additional, and Machado, Pedro M, additional

Published
2024
Full Text
View/download PDF

20. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis:Results From the European Spondyloarthritis Research Collaboration Network

Author

Hellamand, Pasoon, van de Sande, Marleen G.H., Ørnbjerg, Lykke M., Klausch, Thomas, Eklund, Kari K., Relas, Heikki, Santos, Maria J., Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Østergaard, Mikkel, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Fagerli, Karen M., Castrejón, Isabel, Gudbjornsson, Bjorn, Love, Thorvardur J., Vencovský, Jiří, Nekvindová, Lucie, Rotar, Žiga, Tomšič, Matija, Díaz-González, Federico, Kenar, Gökçe, Tuğsal, Handan Y., Iannone, Florenzo, Ramonda, Roberta, Codreanu, Catalin, Mogosan, Corina, Nissen, Michael J., Möller, Burkhard, Hetland, Merete L., van der Horst-Bruinsma, Irene E., Hellamand, Pasoon, van de Sande, Marleen G.H., Ørnbjerg, Lykke M., Klausch, Thomas, Eklund, Kari K., Relas, Heikki, Santos, Maria J., Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Østergaard, Mikkel, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Fagerli, Karen M., Castrejón, Isabel, Gudbjornsson, Bjorn, Love, Thorvardur J., Vencovský, Jiří, Nekvindová, Lucie, Rotar, Žiga, Tomšič, Matija, Díaz-González, Federico, Kenar, Gökçe, Tuğsal, Handan Y., Iannone, Florenzo, Ramonda, Roberta, Codreanu, Catalin, Mogosan, Corina, Nissen, Michael J., Möller, Burkhard, Hetland, Merete L., and van der Horst-Bruinsma, Irene E.

Abstract

Objective Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. Methods Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan–Meier estimator. Results We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80–0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81–0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). Conclusion Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management., Objective: Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. Methods: Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan–Meier estimator. Results: We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80–0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81–0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). Conclusion: Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management.

Published
2024

21. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor:results from 13 European registries

Author

Linde, Louise, Ørnbjerg, Lykke M., Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Di Giuseppe, Daniela, Wallman, Johan K., Gudbjornsson, Bjorn, Love, Thorvardur Jon, Nordström, Dan C., Yli-Kerttula, Timo, Nekvindová, Lucie, Vencovský, Jiří, Iannone, Florenzo, Cauli, Alberto, Loft, Anne Gitte, Glintborg, Bente, Laas, Karin, Rotar, Ziga, Tomšič, Matija, MacFarlane, Gary J., Möller, Burkhard, Van De Sande, Marleen, Codreanu, Catalin, Nissen, Michael J., Birlik, Merih, Erten, Sukran, Santos, Maria J., Vieira-Sousa, Elsa, Hetland, Merete L., Østergaard, Mikkel, Linde, Louise, Ørnbjerg, Lykke M., Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Di Giuseppe, Daniela, Wallman, Johan K., Gudbjornsson, Bjorn, Love, Thorvardur Jon, Nordström, Dan C., Yli-Kerttula, Timo, Nekvindová, Lucie, Vencovský, Jiří, Iannone, Florenzo, Cauli, Alberto, Loft, Anne Gitte, Glintborg, Bente, Laas, Karin, Rotar, Ziga, Tomšič, Matija, MacFarlane, Gary J., Möller, Burkhard, Van De Sande, Marleen, Codreanu, Catalin, Nissen, Michael J., Birlik, Merih, Erten, Sukran, Santos, Maria J., Vieira-Sousa, Elsa, Hetland, Merete L., and Østergaard, Mikkel

Abstract

Objectives In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results In the pooled cohort (n = 13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6954, n = 5275 and n = 13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96–0.98); disease duration, years (<2 years as reference): 2–3 years: 1.20 (0.89–1.60), 4–9 years: 1.42 (1.09–1.84), ≥10 years: 1.66 (1.26–2.20); men vs women: 1.85 (1.54–2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22–1.89) and 1 mm increase in patient fatigue score: 0.99 (0.98–0.99). Conclusion Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level., Objectives: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results: In the pooled cohort (n=13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n=6954, n=5275 and n=13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (<2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1mm increase in patient fatigue score: 0.99 (0.98-0.99). Conclusion: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.

Published
2024

22. Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

Author

Hellamand, Pasoon, primary, van de Sande, Marleen G. H., additional, Ørnbjerg, Lykke M., additional, Klausch, Thomas, additional, Eklund, Kari K., additional, Relas, Heikki, additional, Santos, Maria J., additional, Vieira‐Sousa, Elsa, additional, Loft, Anne G., additional, Glintborg, Bente, additional, Østergaard, Mikkel, additional, Lindström, Ulf, additional, Wallman, Johan K., additional, Michelsen, Brigitte, additional, Fagerli, Karen M., additional, Castrejón, Isabel, additional, Gudbjornsson, Bjorn, additional, Love, Thorvardur J., additional, Vencovský, Jiří, additional, Nekvindová, Lucie, additional, Rotar, Žiga, additional, Tomšič, Matija, additional, Díaz‐González, Federico, additional, Kenar, Gökçe, additional, Tuğsal, Handan Y., additional, Iannone, Florenzo, additional, Ramonda, Roberta, additional, Codreanu, Catalin, additional, Mogosan, Corina, additional, Nissen, Michael J., additional, Möller, Burkhard, additional, Hetland, Merete L., additional, and van der Horst‐Bruinsma, Irene E., additional

Published
2024
Full Text
View/download PDF

23. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network

Author

Hellamand, Pasoon, primary, van de Sande, Marleen, additional, Ørnbjerg, Lykke MIdtbøll, additional, Klausch, Thomas, additional, Nurmohamed, Michael T, additional, van Vollenhoven, Ronald F, additional, Nordström, Dan, additional, Hokkanen, Anna Mari, additional, Santos, Maria Jose, additional, Vieira-Sousa, Elsa, additional, Loft, Anne G, additional, Glintborg, Bente, additional, Hetland, Merete Lund, additional, Lindström, Ulf, additional, Wallman, Johan K, additional, Michelsen, Brigitte, additional, Klami Kristianslund, Eirik, additional, Ciurea, Adrian, additional, Nissen, Michael S, additional, Codreanu, Catalin, additional, Mogosan, Corina, additional, Macfarlane, Gary J, additional, Rotariu, Ovidiu, additional, Rotar, Ziga, additional, Tomšič, Matija, additional, Castrejon, Isabel, additional, Otero-Varela, Lucia, additional, Gudbjornsson, Bjorn, additional, Geirsson, Arni Jon, additional, Vencovský, Jiří, additional, Pavelka, Karel, additional, Gulle, Semih, additional, Zengin, Berrin, additional, Iannone, Florenzo, additional, Foti, Rosario, additional, Ostergaard, Mikkel, additional, and van der Horst-Bruinsma, Irene, additional

Published
2023
Full Text
View/download PDF

28. The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up

Author

Špiritović, Maja, Heřmánková, Barbora, Oreská, Sabína, Štorkánová, Hana, Růžičková, Olga, Vernerová, Lucia, Klein, Martin, Kubínová, Kateřina, Šmucrová, Hana, Rathouská, Adéla, Česák, Petr, Komarc, Martin, Bunc, Václav, Pavelka, Karel, Šenolt, Ladislav, Mann, Heřman, Vencovský, Jiří, and Tomčík, Michal

Published
2021
Full Text
View/download PDF

30. S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.

Author

Švec, Xiao, Štorkánová, Hana, Trinh-Minh, Thuong, Tran, Manh Cuong, Štorkánová, Lenka, Hulejová, Hana, Oreská, Sabína, Heřmánková, Barbora, Bečvář, Radim, Pavelka, Karel, Vencovský, Jiří, Klingelhöfer, Jörg, Hussain, Rizwan I, Hallén, Jonas, Šenolt, Ladislav, Distler, Jörg H W, and Tomčík, Michal

Subjects
DRUG efficacy, BIOLOGICAL models, COLLAGEN, TRANSFORMING growth factors-beta, DISEASE progression, FIBROBLASTS, ANIMAL experimentation, SKIN, FIBROSIS, MONOCLONAL antibodies, INTERLEUKIN-1, REGRESSION analysis, DERMIS, GENE expression profiling, RESEARCH funding, INFLAMMATORY mediators, MICE, EVALUATION
Abstract

Objectives Our previous studies have demonstrated that the Damage Associated Molecular Pattern (DAMP) protein, S100A4, is overexpressed in the involved skin and peripheral blood of patients with SSc. It is associated with skin and lung involvement, and disease activity. By contrast, lack of S100A4 prevented the development of experimental dermal fibrosis. Herein we aimed to evaluate the effect of murine anti-S100A4 mAb 6B12 in the treatment of preestablished experimental dermal fibrosis. Methods The effects of 6B12 were assessed at therapeutic dosages in a modified bleomycin-induced dermal fibrosis mouse model by evaluating fibrotic (dermal thickness, proliferation of myofibroblasts, hydroxyproline content, phosphorylated Smad3-positive cell count) and inflammatory (leukocytes infiltrating the lesional skin, systemic levels of selected cytokines and chemokines) outcomes, and transcriptional profiling (RNA sequencing). Results Treatment with 7.5 mg/kg 6B12 attenuated and might even reduce pre-existing dermal fibrosis induced by bleomycin as evidenced by reduction in dermal thickness, myofibroblast count and collagen content. These antifibrotic effects were mediated by the downregulation of TGF-β/Smad signalling and partially by reducing the number of leukocytes infiltrating the lesional skin and decrease in the systemic levels of IL-1α, eotaxin, CCL2 and CCL5. Moreover, transcriptional profiling demonstrated that 7.5 mg/kg 6B12 also modulated several profibrotic and proinflammatory processes relevant to the pathogenesis of SSc. Conclusion Targeting S100A4 by the 6B12 mAb demonstrated potent antifibrotic and anti-inflammatory effects on bleomycin-induced dermal fibrosis and provided further evidence for the vital role of S100A4 in the pathophysiology of SSc. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.

Author

Linde, Louise, Ørnbjerg, Lykke M, Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Giuseppe, Daniela Di, Wallman, Johan K, Gudbjornsson, Bjorn, Love, Thorvardur Jon, Nordström, Dan C, Yli-Kerttula, Timo, Nekvindová, Lucie, Vencovský, Jiří, Iannone, Florenzo, Cauli, Alberto, Loft, Anne Gitte, Glintborg, Bente, and Laas, Karin

Subjects
PSORIATIC arthritis, CONFIDENCE intervals, ANTI-inflammatory agents, RESEARCH funding, TERMINATION of treatment, LOGISTIC regression analysis, ODDS ratio, FATIGUE (Physiology), DISEASE remission
Abstract

Objectives In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results In the pooled cohort (n  = 13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n  = 6954, n  = 5275 and n  = 13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96–0.98); disease duration, years (<2 years as reference): 2–3 years: 1.20 (0.89–1.60), 4–9 years: 1.42 (1.09–1.84), ≥10 years: 1.66 (1.26–2.20); men vs women: 1.85 (1.54–2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22–1.89) and 1 mm increase in patient fatigue score: 0.99 (0.98–0.99). Conclusion Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. What's new in rheumatology

Author

Šenolt, Ladislav, primary, Filková, Mária, additional, Bubová, Kristýna, additional, Závada, Jakub, additional, Tomčík, Michal, additional, Vencovský, Jiří, additional, Tichý, Šimon, additional, and Pavelka, Karel, additional

Published
2023
Full Text
View/download PDF

33. Correction: Štorkánová et al. Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines 2021, 9, 650

Author

Štorkánová, Hana, primary, Štorkánová, Lenka, additional, Navrátilová, Adéla, additional, Bečvář, Viktor, additional, Hulejová, Hana, additional, Oreská, Sabína, additional, Heřmánková, Barbora, additional, Špiritović, Maja, additional, Bečvář, Radim, additional, Pavelka, Karel, additional, Vencovský, Jiří, additional, Distler, Jörg H. W., additional, Šenolt, Ladislav, additional, and Tomčík, Michal, additional

Published
2023
Full Text
View/download PDF

34. 255th ENMC workshop: Muscle imaging in idiopathic inflammatory myopathies. 15th January, 16th January and 22nd January 2021 – virtual meeting and hybrid meeting on 9th and 19th September 2022 in Hoofddorp, The Netherlands

Author

de Visser, Marianne, primary, Carlier, Pierre, additional, Vencovský, Jiří, additional, Kubínová, Kateřina, additional, Preusse, Corinna, additional, Albayda, Jemima, additional, Allenbach, Yves, additional, Benveniste, Olivier, additional, Diederichsen, Louise, additional, Demonceau, Georges, additional, de Groot, Ingrid, additional, van der Kooi, Anneke, additional, Machado, Pedro, additional, Mammen, Andrew, additional, Reyngoudt, Harmen, additional, Mischke, Roland, additional, Morrow, Jasper, additional, Pipitone, Nicoló, additional, Rataj, Michael, additional, Rider, Lisa, additional, Schmidt, Jens, additional, Stenzel, Werner, additional, Tasca, Giorgio, additional, de Visser, Marianne, additional, and Verhamme, Camiel, additional

Published
2023
Full Text
View/download PDF

35. 130 Low Gene Copy Numbers (GCN) of complement C4 and C4A deficiency are highly significant genetic risk factors for idiopathic inflammatory myopathies and its major subgroups

Author

Zhou, Danlei, primary, King, Emily, additional, Rothwell, Simon, additional, Kryštůfková, Olga, additional, Notarnicola, Antonella, additional, Coss, Samantha, additional, Aziz, Rabheh, additional, Miller, Katherine, additional, Dang, Amanda, additional, Yu, Richard, additional, Drew, Joanne, additional, Lundstrom, Emeli, additional, Pachman, Lauren, additional, Mamyrova, Gulnara, additional, Curiel, Rodolfo, additional, De Paepe, Boel, additional, De Bleecker, Jan, additional, Payton, Antony, additional, Ollier, William, additional, O'Hanlon, Terrance, additional, Targoff, Ira, additional, Flegel, Willy, additional, Sivaraman, Vidya, additional, Obele, Edward, additional, Akoghlanian, Shoghik, additional, Driest, Kyla, additional, Spencer, Charles, additional, Ling Wu, Yee, additional, Nagaraja, Haikady, additional, Ardoin, Stacy, additional, Chinoy, Hector, additional, Rider, Lisa, additional, Miller, Frederick, additional, Lundberg, Ingrid, additional, Padyukov, Leonid, additional, Vencovský, Jiří, additional, Lamb, Janine, additional, and Yu, Chack-Yung, additional

Published
2023
Full Text
View/download PDF

39. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries

Author

Linde, Louise, primary, Ørnbjerg, Lykke M, additional, Georgiadis, Stylianos, additional, H. Rasmussen, Simon, additional, Lindström, Ulf, additional, Askling, Johan, additional, Michelsen, Brigitte, additional, Di Giuseppe, Daniela, additional, Wallman, Johan K, additional, Gudbjornsson, Bjorn, additional, Love, Thorvardur Jon, additional, Nordström, Dan C, additional, Yli-Kerttula, Timo, additional, Nekvindová, Lucie, additional, Vencovský, Jiří, additional, Iannone, Florenzo, additional, Cauli, Alberto, additional, Loft, Anne Gitte, additional, Glintborg, Bente, additional, Laas, Karin, additional, Rotar, Ziga, additional, Tomšič, Matija, additional, Macfarlane, Gary J, additional, Möller, Burkhard, additional, van de Sande, Marleen, additional, Codreanu, Catalin, additional, Nissen, Michael J, additional, Birlik, Merih, additional, Erten, Sukran, additional, Santos, Maria J, additional, Vieira-Sousa, Elsa, additional, Hetland, Merete L, additional, and Østergaard, Mikkel, additional

Published
2023
Full Text
View/download PDF

42. New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis

Author

Navrátilová, Adéla, primary, Bečvář, Viktor, additional, Hulejová, Hana, additional, Tomčík, Michal, additional, Štolová, Lucie, additional, Mann, Heřman, additional, Růžičková, Olga, additional, Šléglová, Olga, additional, Závada, Jakub, additional, Pavelka, Karel, additional, Vencovský, Jiří, additional, Šenolt, Ladislav, additional, and Andrés Cerezo, Lucie, additional

Published
2023
Full Text
View/download PDF

43. Complement C4 gene copy number variations and polymorphisms, autoantibodies, and clinical manifestations of juvenile dermatomyositis– a multi-center study

Author

Coss, Samantha Lynn, primary, Aziz, Rabheh Abdul, additional, Zhou, Danlei, additional, Zhou, Bi, additional, Miller, Katherine, additional, Wu, Yee Ling, additional, Ardoin, Stacy, additional, Oberle, Edward, additional, Driest, Kyla, additional, Al Ahmed, Ohoud, additional, Patwardhan, Anjali, additional, Akoghlanian, Shoghik, additional, Sivaraman, Vidya, additional, Barbar-Smiley, Fatima, additional, Drew, Joanne, additional, Spencer, Charles, additional, Pachman, Lauren, additional, Morgan, Gabrielle, additional, Mamyrova, Gulnara, additional, Curiel, Rodolfo, additional, Jones, Olcay, additional, O’Hanlon, Terry, additional, Rider, Lisa, additional, Miller, Frederick, additional, Padyukov, Leonid, additional, Lundberg, Ingrid, additional, Notarnicola, Antonella, additional, Vencovský, Jiří, additional, Stibůrková, Blanka, additional, Kryštůfková, Olga, additional, and Yu, Chack-Yung, additional

Published
2023
Full Text
View/download PDF

44. OA18 Smoking and high BMI are associated with reductions in TNF inhibitor response in psoriatic arthritis: results from 12 European countries

Author

Jones, Gareth T, primary, Rotariu, Ovidiu, additional, Michelsen, Brigitte, additional, Glintborg, Bente, additional, Gudbjornsson, Bjorn, additional, Love, Thorvardur J, additional, Nordström, Dan, additional, Sokka, Tuulikki, additional, Vencovský, Jiří, additional, Horák, Pavel, additional, Rotar, Ziga, additional, Tomšič, Matija, additional, van der Sande, Marleen, additional, Nissen, Michael J, additional, Möller, Burkhard, additional, Codreanu, Catalin, additional, Wallman, Johan K, additional, Fagerli, Karen M, additional, Rasmussen, Simon H, additional, Ørnbjerg, Lykke M, additional, Santos, Maria J, additional, Carvalho, Pedro, additional, Hetland, Merete L, additional, Østergaard, Mikkel, additional, and Macfarlane, Gary J, additional

Published
2023
Full Text
View/download PDF

45. Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration

Author

Linde, Louise; https://orcid.org/0000-0003-0863-1352, Ørnbjerg, Lykke M, Rasmussen, Simon H, Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K, Kvien, Tore K, Rodrigues, Ana M, Santos, Maria J, Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Macfarlane, Gary J, Heddle, Maureen, et al, Linde, Louise; https://orcid.org/0000-0003-0863-1352, Ørnbjerg, Lykke M, Rasmussen, Simon H, Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K, Kvien, Tore K, Rodrigues, Ana M, Santos, Maria J, Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Macfarlane, Gary J, Heddle, Maureen, and et al

Abstract

BACKGROUND: In European axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) clinical registries, we aimed to investigate commonalities and differences in (1) set-up, clinical data collection; (2) data availability and completeness; and (3) wording, recall period, and scale used for selected patient-reported outcome measures (PROMs). METHODS: Data was obtained as part of the EuroSpA Research Collaboration Network and consisted of (1) an online survey and follow-up interview, (2) upload of real-world data, and (3) selected PROMs included in the online survey. RESULTS: Fifteen registries participated, contributing 33,948 patients (axSpA: 21,330 (63%), PsA: 12,618 (37%)). The reported coverage of eligible patients ranged from 0.5 to 100%. Information on age, sex, biological/targeted synthetic disease-modifying anti-rheumatic drug treatment, disease duration, and C-reactive protein was available in all registries with data completeness between 85% and 100%. All PROMs (Bath Ankylosing Spondylitis Disease Activity and Functional Indices, Health Assessment Questionnaire, and patient global, pain and fatigue assessments) were more complete after 2015 (68-86%) compared to prior (50-79%). Patient global, pain and fatigue assessments showed heterogeneity between registries in terms of wording, recall periods, and scale. CONCLUSION: Important heterogeneity in registry design and data collection across fifteen European axSpA and PsA registries was observed. Several core measures were widely available, and an increase in data completeness of PROMs in recent years was identified. This study might serve as a basis for examining how differences in data collection across registries may impact the results of collaborative research in the future.

Published
2023

46. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Author

Michelsen, Brigitte; https://orcid.org/0000-0003-0103-2840, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Möller, Burkhard; https://orcid.org/0000-0001-8769-6167, Ørnbjerg, Lykke Midtbøll; https://orcid.org/0000-0002-7832-6831, Závada, Jakub, Glintborg, Bente; https://orcid.org/0000-0002-8931-8482, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo; https://orcid.org/0000-0003-0474-5344, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Žiga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovský, Jiří; https://orcid.org/0000-0002-0851-0713, Loft, Anne Gitte; https://orcid.org/0000-0001-6374-841X, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José; https://orcid.org/0000-0002-7946-1365, et al, Michelsen, Brigitte; https://orcid.org/0000-0003-0103-2840, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Möller, Burkhard; https://orcid.org/0000-0001-8769-6167, Ørnbjerg, Lykke Midtbøll; https://orcid.org/0000-0002-7832-6831, Závada, Jakub, Glintborg, Bente; https://orcid.org/0000-0002-8931-8482, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo; https://orcid.org/0000-0003-0474-5344, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Žiga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovský, Jiří; https://orcid.org/0000-0002-0851-0713, Loft, Anne Gitte; https://orcid.org/0000-0001-6374-841X, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José; https://orcid.org/0000-0002-7946-1365, and et al

Abstract

This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021-April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.

Published
2023

48. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries

Author

Linde, Louise, Ørnbjerg, Lykke M, Georgiadis, Stylianos, Rasmussen, Simon H, Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Di Giuseppe, Daniela, Wallman, Johan K, Gudbjornsson, Bjorn, Love, Thorvardur Jon, Nordström, Dan C, Yli-Kerttula, Timo, Nekvindová, Lucie, Vencovský, Jiří, Iannone, Florenzo, Cauli, Alberto, Loft, Anne Gitte, Glintborg, Bente, Laas, Karin, Rotar, Ziga, Tomšič, Matija, Macfarlane, Gary J, Möller, Burkhard, van de Sande, Marleen, Codreanu, Catalin, Nissen, Michael J, Birlik, Merih, Erten, Sukran, Santos, Maria J, Vieira-Sousa, Elsa, Hetland, Merete L, and Østergaard, Mikkel

Subjects
610 Medicine & health
Abstract

OBJECTIVES In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. METHODS Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes, were defined as common predictors. RESULTS In the pooled cohort (n = 13 369), six-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6,954, n = 5,275 and n = 13 369, respectively). Baseline predictors of remission, moderate response and 12-month drug retention were identified, five common across all three outcomes. Odds ratios (95% confidence interval) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (< 2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP >10 vs ≤ 10 mg/l: 1.52 (1.22-1.89) and one mm increase in patient fatigue score: 0.99 (0.98-0.99). CONCLUSION Baseline predictors of remission, response and adherence to TNFi were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalisable from the country- to disease-level.

Published
2023
Full Text
View/download PDF

50. Low copy numbers of complementC4andC4Adeficiency are risk factors for myositis, its subgroups and autoantibodies

Author

Zhou, Danlei, primary, King, Emily H, additional, Rothwell, Simon, additional, Krystufkova, Olga, additional, Notarnicola, Antonella, additional, Coss, Samantha, additional, Abdul-Aziz, Rabheh, additional, Miller, Katherine E, additional, Dang, Amanda, additional, Yu, G Richard, additional, Drew, Joanne, additional, Lundström, Emeli, additional, Pachman, Lauren M, additional, Mamyrova, Gulnara, additional, Curiel, Rodolfo V, additional, De Paepe, Boel, additional, De Bleecker, Jan L, additional, Payton, Antony, additional, Ollier, William, additional, O'Hanlon, Terrance P, additional, Targoff, Ira N, additional, Flegel, Willy A, additional, Sivaraman, Vidya, additional, Oberle, Edward, additional, Akoghlanian, Shoghik, additional, Driest, Kyla, additional, Spencer, Charles H, additional, Wu, Yee Ling, additional, Nagaraja, Haikady N, additional, Ardoin, Stacy P, additional, Chinoy, Hector, additional, Rider, Lisa G, additional, Miller, Frederick W, additional, Lundberg, Ingrid E, additional, Padyukov, Leonid, additional, Vencovský, Jiří, additional, Lamb, Janine A, additional, and Yu, Chack-Yung, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results